Literature DB >> 17923691

Protein kinase C-dependent control of Bcl-x alternative splicing.

Timothée Revil1, Johanne Toutant, Lulzim Shkreta, Daniel Garneau, Philippe Cloutier, Benoit Chabot.   

Abstract

The alternative splicing of Bcl-x generates the proapoptotic Bcl-x(S) protein and the antiapoptotic isoform Bcl-x(L). Bcl-x splicing is coupled to signal transduction, since ceramide, hormones, and growth factors alter the ratio of the Bcl-x isoforms in different cell lines. Here we report that the protein kinase C (PKC) inhibitor and apoptotic inducer staurosporine switches the production of Bcl-x towards the x(S) mRNA isoform in 293 cells. The increase in Bcl-x(S) elicited by staurosporine likely involves signaling events that affect splicing decisions, because it requires active transcription and no new protein synthesis and is independent of caspase activation. Moreover, the increase in Bcl-x(S) is reproduced with more specific inhibitors of PKC. Alternative splicing of the receptor tyrosine kinase gene Axl is similarly affected by staurosporine in 293 cells. In contrast to the case for 293 cells, PKC inhibitors do not influence the alternative splicing of Bcl-x and Axl in cancer cell lines, suggesting that these cells have sustained alterations that uncouple splicing decisions from PKC-dependent signaling. Using minigenes, we show that an exonic region located upstream of the Bcl-x(S) 5' splice site is important to mediate the staurosporine shift in Bcl-x splicing. When transplanted to other alternative splicing units, portions of this region confer splicing modulation and responsiveness to staurosporine, suggesting the existence of factors that couple splicing decisions with PKC signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923691      PMCID: PMC2169420          DOI: 10.1128/MCB.00565-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  97 in total

1.  Promoter choice influences alternative splicing and determines the balance of isoforms expressed from the mouse bcl-X gene.

Authors:  A Pecci; L R Viegas; J L Baranao; M Beato
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

2.  Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.

Authors:  B Pilch; E Allemand; M Facompré; C Bailly; J F Riou; J Soret; J Tazi
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

3.  Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy.

Authors:  L Langzam; R Koren; R Gal; V Kugel; A Paz; A Farkas; S R Sampson
Journal:  Am J Clin Pathol       Date:  2001-09       Impact factor: 2.493

4.  Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1.

Authors:  R Zinck; M A Cahill; M Kracht; C Sachsenmaier; R A Hipskind; A Nordheim
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

5.  Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains.

Authors:  L Lindenboim; C Borner; R Stein
Journal:  Cell Death Differ       Date:  2001-09       Impact factor: 15.828

6.  FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1.

Authors:  C E Chalfant; B Ogretmen; S Galadari; B J Kroesen; B J Pettus; Y A Hannun
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

7.  Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms.

Authors:  C A Belmokhtar; J Hillion; E Ségal-Bendirdjian
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

8.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

9.  Ceramide inactivates cellular protein kinase Calpha.

Authors:  J Y Lee; Y A Hannun; L M Obeid
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

10.  Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death.

Authors:  L A Casciola-Rosen; D K Miller; G J Anhalt; A Rosen
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

View more
  37 in total

1.  Protein Kinase C Theta Modulates PCMT1 through hnRNPL to Regulate FOXP3 Stability in Regulatory T Cells.

Authors:  E Ilker Ozay; Sudarvili Shanthalingam; Joe A Torres; Barbara A Osborne; Gregory N Tew; Lisa M Minter
Journal:  Mol Ther       Date:  2020-06-15       Impact factor: 11.454

2.  TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription.

Authors:  Marta Montes; Alexandre Cloutier; Noemí Sánchez-Hernández; Laetitia Michelle; Bruno Lemieux; Marco Blanchette; Cristina Hernández-Munain; Benoit Chabot; Carlos Suñé
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

3.  The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.

Authors:  Lulzim Shkreta; Laetitia Michelle; Johanne Toutant; Michel L Tremblay; Benoit Chabot
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

Review 4.  Emerging mechanisms and consequences of calcium regulation of alternative splicing in neurons and endocrine cells.

Authors:  Aleh Razanau; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2013-06-26       Impact factor: 9.261

5.  Insulin promotes neuronal survival via the alternatively spliced protein kinase CδII isoform.

Authors:  André Apostolatos; Shijie Song; Sandra Acosta; Mishka Peart; James E Watson; Paula Bickford; Denise R Cooper; Niketa A Patel
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

6.  Functional implications of structural predictions for alternative splice proteins expressed in Her2/neu-induced breast cancers.

Authors:  Rajasree Menon; Ambrish Roy; Srayanta Mukherjee; Saveliy Belkin; Yang Zhang; Gilbert S Omenn
Journal:  J Proteome Res       Date:  2011-10-28       Impact factor: 4.466

7.  Multiple and specific mRNA processing targets for the major human hnRNP proteins.

Authors:  Julian P Venables; Chu-Shin Koh; Ulrike Froehlich; Elvy Lapointe; Sonia Couture; Lyna Inkel; Anne Bramard; Eric R Paquet; Valérie Watier; Mathieu Durand; Jean-François Lucier; Julien Gervais-Bird; Karine Tremblay; Panagiotis Prinos; Roscoe Klinck; Sherif Abou Elela; Benoit Chabot
Journal:  Mol Cell Biol       Date:  2008-07-21       Impact factor: 4.272

8.  A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17.

Authors:  Suli Liu; Hogune Im; Amos Bairoch; Massimo Cristofanilli; Rui Chen; Eric W Deutsch; Stephen Dalton; David Fenyo; Susan Fanayan; Chris Gates; Pascale Gaudet; Marina Hincapie; Samir Hanash; Hoguen Kim; Seul-Ki Jeong; Emma Lundberg; George Mias; Rajasree Menon; Zhaomei Mu; Edouard Nice; Young-Ki Paik; Mathias Uhlen; Lance Wells; Shiaw-Lin Wu; Fangfei Yan; Fan Zhang; Yue Zhang; Michael Snyder; Gilbert S Omenn; Ronald C Beavis; William S Hancock
Journal:  J Proteome Res       Date:  2012-12-21       Impact factor: 4.466

9.  Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5' splice site selection.

Authors:  Anyu Zhou; Alexander C Ou; Aeri Cho; Edward J Benz; Shu-Ching Huang
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

Review 10.  A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.

Authors:  Gilbert S Omenn; Yuanfang Guan; Rajasree Menon
Journal:  J Proteomics       Date:  2014-05-05       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.